SUTRO BIOPHARMA, INC. Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31)
SUTRO BIOPHARMA, INC. (STRO) reported Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) of $10.33 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2020-08-06.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 · last filed 2020-08-06
- SUTRO BIOPHARMA, INC. cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for the quarter ending 2019-03-31 was $10.33M.
| Period end | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 3 month |
|---|---|
| 2019-03-31 | $10.33M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |